Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Ionis Pharmaceuticals Inc

Healthcare US IONS

75.66USD
0.30(0.40%)

Last update at 2026-03-10T20:00:00Z

Day Range

74.5177.03
LowHigh

52 Week Range

36.5654.44
LowHigh

Fundamentals

  • Previous Close 75.36
  • Market Cap5456.90M
  • Volume2738207
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-354.60800M
  • Revenue TTM776.62M
  • Revenue Per Share TTM5.40
  • Gross Profit TTM -257.86600M
  • Diluted EPS TTM-2.67

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -258.00000M -30.00000M -170.00000M 347.00M -76.15600M
Minority interest 0.00000M 0.00000M -35.48000M 9.12M -58.75600M
Net income -270.00000M -29.00000M -487.00000M 294.00M 273.74M
Selling general administrative 150.30M 170.90M 354.00M 287.00M 244.62M
Selling and marketing expenses 0.70M 15.10M - - -
Gross profit 573.00M 799.00M 717.00M 1119.00M 597.85M
Reconciled depreciation 22.11M 19.56M 17.16M 15.99M 12.53M
Ebit -411.00000M -30.00000M -189.16000M 350.01M -74.08200M
Ebitda -561.00000M -21.00000M -172.00000M 366.00M -61.55400M
Depreciation and amortization -150.00000M 9.00M 17.16M 15.99M 12.53M
Non operating income net other 160.33M 10.39M 47.04M 29.65M 30.00M
Operating income -411.00000M -30.00000M -172.00000M 366.00M -61.37200M
Other operating expenses 998.00M 840.00M 901.00M 757.00M 661.05M
Interest expense 8.12M 4.30M 44.99M 49.00M 44.79M
Tax provision 11.74M -1.00000M 317.00M 43.51M -291.14100M
Interest income - - - 3.44M 14.60M
Net interest income -8.12200M -9.20000M -44.99000M -48.76800M -44.78900M
Extraordinary items - - - - 332.10M
Non recurring - - - - -
Other items - - - - -
Income tax expense 12.00M -1.00000M 317.00M 44.00M -291.14100M
Total revenue 587.00M 810.00M 729.00M 1123.00M 599.67M
Total operating expenses 984.00M 829.00M 889.00M 753.00M 659.23M
Cost of revenue 14.00M 11.00M 12.00M 4.00M 1.82M
Total other income expense net 153.00M -5.11300M 2.00M -19.00000M 30.00M
Discontinued operations - - - - -
Net income from continuing ops -269.72200M -28.59700M -486.76600M 303.26M 214.99M
Net income applicable to common shares -269.72200M -28.59700M -451.28600M 294.15M 273.74M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 2990.07M 2534.00M 2612.00M 2390.00M 3233.00M
Intangible assets - - 29.00M 27.94M 25.67M
Earning assets - - - - -
Other current assets 184.45M 190.00M 168.00M 162.00M 158.00M
Total liab 2603.39M 1961.00M 1840.00M 1547.00M 1548.00M
Total stockholder equity 386.69M 573.00M 772.00M 843.00M 1471.00M
Deferred long term liab - - - - -
Other current liab 217.77M 195.54M 127.57M -128.36000M 136.91M
Common stock 0.14M 0.14M 0.14M 0.14M 0.14M
Capital stock 0.14M 0.14M 0.14M 0.14M 0.14M
Retained earnings -1795.91100M -1429.62500M -1159.90300M -1249.36800M -707.53400M
Other liab - 287.77M 352.00M 424.00M 490.06M
Good will - - - - -
Other assets - 34.97M 319.00M 77.97M 310.59M
Cash 399.27M 1987.00M 2115.00M 1892.00M 2500.00M
Cash and equivalents - - - - -
Total current liabilities 448.09M 312.00M 241.00M 290.00M 273.00M
Current deferred revenue 151.13M 91.00M 98.00M 108.00M 118.00M
Net debt 1054.27M -642.00000M -954.00000M -1143.00000M -1790.00000M
Short term debt 53.16M 7.54M 3.53M 293.16M 2.03M
Short long term debt 53.16M 7.54M 3.53M 300.46M 2.03M
Short long term debt total 1453.54M 1345.00M 1161.00M 749.00M 710.00M
Other stockholder equity 2182.45M 2059.96M 1964.43M 2113.30M 2203.68M
Property plant equipment - 74.29M 178.07M 181.08M 153.65M
Total current assets 2641.85M 2203.00M 2345.00M 2130.00M 2721.00M
Long term investments - - - - 10.00M
Net tangible assets - 572.89M 742.73M 815.41M 1445.42M
Short term investments 1931.93M 1710.40M 1245.78M 1494.71M 1816.26M
Net receivables 97.78M 26.00M 62.00M 76.00M 63.00M
Long term debt 1229.50M 1182.72M 1221.15M 515.70M 769.96M
Inventory 28.43M 22.03M 24.81M 21.96M 18.18M
Accounts payable 26.03M 17.92M 11.90M 17.20M 16.07M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - 213.45M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -32.64500M -57.48000M -32.66800M -21.07100M -25.29000M
Additional paid in capital - - - - -
Common stock total equity - 0.14M 0.14M 0.14M 0.14M
Preferred stock total equity - - - - -
Retained earnings total equity - -1429.62500M -1159.90300M -1249.36800M -707.53400M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 62.29M 75.00M 59.99M 51.06M 358.00M
Deferred long term asset charges - - - - -
Non current assets total 348.22M 331.00M 267.00M 260.00M 512.00M
Capital lease obligations 170.88M 178.94M - - -
Long term debt total - 1175.59M 1221.15M 515.70M 769.96M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 24.73M -262.63600M 212.81M 315.52M -4.99200M
Change to liabilities - 64.37M -42.58700M -5.66300M 23.40M
Total cashflows from investing activities - -262.63600M 194.91M 274.48M -41.27400M
Net borrowings - -50.68600M 418.30M 313.57M -22.11200M
Total cash from financing activities 644.08M -55.29500M 245.93M -596.60900M 100.02M
Change to operating activities - 32.38M -36.17600M 50.82M -20.07100M
Net income -366.28600M -269.72200M -28.59700M -486.76600M 303.26M
Change in cash 122.79M -592.71900M 471.53M -285.62300M 404.47M
Begin period cash flow 276.47M 869.19M 397.66M 683.29M 278.82M
End period cash flow 399.27M 276.47M 869.19M 397.66M 683.29M
Total cash from operating activities -307.51300M -274.37000M 30.80M 35.89M 345.72M
Issuance of capital stock 9.02M 6.37M 11.56M 52.04M 119.66M
Depreciation 22.50M 22.11M 19.56M 17.16M 15.99M
Other cashflows from investing activities - 249.71M -5.94600M -5.92800M -5.37700M
Dividends paid - 10.95M 16.73M - 165.61M
Change to inventory -6.39200M 2.77M -2.84100M -1.26100M -5.41100M
Change to account receivables -72.05900M 36.36M 5.05M -22.00000M -44.17800M
Sale purchase of stock - -10.95300M -16.72500M -90.54800M -34.39200M
Other cashflows from financing activities 1082.74M -0.02900M 570.02M -558.09700M 203.29M
Change to netincome - 103.05M 130.92M 528.80M 161.34M
Capital expenditures 28.01M 20.10M 17.90M 41.05M 36.28M
Change receivables - - - - -
Cash flows other operating - -204.34500M -66.66900M -64.90000M -183.12300M
Exchange rate changes - - -0.11100M 0.62M -
Cash and cash equivalents changes - -592.30100M 471.53M -285.62300M 404.47M
Change in working capital -77.26000M 7.57M -113.81800M -73.55500M -168.70800M
Stock based compensation 105.81M 100.26M 120.68M 230.12M 146.57M
Other non cash items 29.94M -134.58800M 7.67M 35.66M 55.69M
Free cash flow -335.52400M -294.46900M 12.90M -5.15600M 309.44M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IONS
Ionis Pharmaceuticals Inc		 0.30 0.40% 75.66 - 90.91 7.72 15.74 6.61 -22.0777
NVO
Novo Nordisk A/S		 -1.06 2.66% 38.72 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 38.88 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 38.30 8.31% 499.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.57 1.22% 772.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Ionis Pharmaceuticals Inc

2855 Gazelle Court, Carlsbad, CA, United States, 92010

Key Executives

Name Title Year Born
Dr. Brett P. Monia Ph.D. Founder, CEO & Director 1961
Ms. Elizabeth L. Hougen Exec. VP of Fin. & CFO 1962
Ms. Onaiza Cadoret-Manier Exec. VP, Chief Global Product Strategy & Operations Officer 1965
Mr. Patrick R. O'Neil Esq. Exec. VP, Chief Legal Officer, Gen. Counsel & Corp. Sec. 1974
Dr. Stanley T. Crooke Scientific Advisor 1945
Ms. B. Lynne Parshall Esq., J.D. Sr. Strategic Advisor & Director 1954
Dr. Eric E. Swayze Ph.D. Exec. VP of Research 1966
Mr. Joel Edwards VP of Corp. Operations 1961
Mr. Darren Gonzales Chief Accounting Officer & Sr. VP NA
Dr. C. Frank Bennett Exec. VP & Chief Scientific Officer 1957

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.